CIDP Treatment Options in 2026: New and Standard

A diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) raises an immediate and practical question: which treatment, and what will it involve. CIDP is one of the more treatable nerve conditions, and the range of options has grown in recent years.

The condition develops when the immune system attacks the protective coating around the nerves outside the brain and spinal cord. That damage disrupts the signals traveling between the body and the brain, producing weakness, numbness, and tingling. Treatment works by calming that immune attack.

No single CIDP treatment is right for everyone. The most suitable choice depends on how severe the condition is, which form of CIDP a person has, their other health conditions, and how their body responds over time.

This guide covers the main treatment options used in 2026, both the long-established ones and the newer arrivals, including how each works, what to expect from it, and how these decisions are made.

How CIDP treatment works

Every CIDP treatment shares the same goal: to quiet the immune system so that it stops attacking the nerves.

Once that attack settles, the protective coating around the nerves has a chance to repair, and signals begin to travel more normally again. This is why strength and sensation often return gradually once an effective treatment is underway.

Timing matters. The protective coating can usually be rebuilt, but if the inflammation continues unchecked, the nerve fibers underneath can also be damaged. That deeper damage is far harder to reverse. Starting treatment early, before significant nerve-fiber loss sets in, offers the best chance of a strong recovery.

Treatment is usually approached in two stages. The first is bringing an active flare under control. The second is keeping the condition stable over the longer term. Some treatments are better suited to the first task and others to the second, and many people move between the two as their condition changes.

First-line treatments for CIDP

Three treatments have the longest track record, and one of them is usually where treatment begins. They work in different ways, so when one is not the right fit, another often is. Across these three, roughly six in ten people respond well, though the figure varies between studies.

Intravenous immunoglobulin (IVIG)

IVIG is often the first treatment a neurologist considers. It is made from antibodies donated by thousands of healthy people and is given through an IV.

The exact way it works is not fully understood, but the donated antibodies appear to neutralize the harmful ones attacking the nerves and to calm the surrounding inflammation.

Treatment usually begins with a larger dose spread over two to five days to bring the condition under control quickly. Smaller maintenance doses follow, often around every three weeks, and are adjusted to whatever keeps symptoms steady. Each infusion takes a few hours, and once the condition has stabilized, many people are able to have their infusions at a center close to home, or at home itself.

Improvement often begins within the first couple of weeks, though the fullest benefit can take several months of regular infusions to build.

Side effects are usually mild. The common ones tend to appear around infusion days:

• Headache, nausea, or a low-grade fever are the most frequent, and staying well hydrated around infusion days helps reduce headaches in particular.
• Feeling washed out for a day or two after an infusion is common, and many people plan a lighter schedule around treatment days.
• More serious reactions, such as blood clots, are uncommon but are part of why the early infusions are monitored.

Corticosteroids

Corticosteroids are anti-inflammatory medicines that lower immune activity. Common examples include prednisone, prednisolone, and dexamethasone. As one of the oldest steroids for CIDP, they are often chosen because they are taken as a tablet and cost considerably less than infusions.

There is more than one way to take them. Some people are prescribed a daily tablet that is slowly tapered over months, while others take a high dose for a few days each month in a repeating cycle. A majority of people respond, and a meaningful share reach a lasting remission. Corticosteroids tend to work more gradually than IVIG, so the full effect can take longer to appear.

The trade-off is side effects, particularly with long-term use. Doctors keep a close watch for several:

• Weight gain and skin changes are among the most visible effects, including thinning of the skin over time.
• Raised blood sugar and higher blood pressure can develop, which need monitoring in anyone already at risk.
• Thinning bones and a greater risk of infection build up with prolonged use, along with mood changes that can affect daily life.

For these reasons, the aim is to use the lowest effective dose for the shortest reasonable time.

It is also worth knowing that a small number of people feel worse rather than better after starting corticosteroids. This is more likely with certain forms of CIDP, which is why close monitoring in the early weeks is important.

Plasma exchange (plasmapheresis)

Plasma exchange, also called plasmapheresis, takes a more direct approach. Rather than changing how the immune system behaves, it physically removes the harmful antibodies from the blood.

During a session, blood is drawn from a vein and passed through a machine that separates out the plasma, the liquid part that carries the antibodies. The blood cells are then returned along with a replacement fluid.

It is usually given as a series of sessions, often five to ten over a couple of weeks, with each lasting a few hours. Many people improve, but the benefit can fade fairly quickly once the sessions stop. For this reason, plasma exchange tends to be used when a rapid response is needed, or when IVIG and corticosteroids have not done enough.

Because it requires reliable vein access and specialized equipment, plasma exchange is carried out in a hospital or specialized center. The side effects are usually manageable:

• Changes in blood pressure can occur during a session and are watched closely by the care team.
• A tingling sensation sometimes develops from the medicine used to keep the blood from clotting in the machine.
• Tiredness afterward is common, and many people find they need to rest following a session.

Maintenance and longer-term options

Once the condition is under control, the goal shifts to keeping it stable with as little disruption to daily life as possible. Several options are designed for this stage, and some of the more recent arrivals offer more flexibility and independence than was available a few years ago.

Subcutaneous immunoglobulin (SCIg)

SCIg is the same antibody treatment as IVIG, with one key difference: it is given under the skin rather than into a vein, and it is usually self-administered at home after some training.

Doses are smaller and more frequent, typically once a week. The main advantage is independence, with no trips to an infusion center, steadier antibody levels, and fewer of the whole-body side effects that can follow a large intravenous dose. The main drawbacks are mild reactions at the injection site, such as redness or swelling, and the commitment of a regular self-injection routine.

Immunoglobulin given under the skin in larger volumes

A more recent version of subcutaneous treatment allows the antibody therapy to be given under the skin in much larger volumes, and far less often, in some cases only about once a month.

It works by pairing the standard antibody treatment with an enzyme that briefly loosens the tissue under the skin so a larger dose can be absorbed comfortably. The enzyme does not treat the CIDP itself; it simply makes the larger, less frequent dose possible.

For people who value the independence of home treatment but find a weekly schedule burdensome, this can be a useful middle ground. It is generally used for maintenance, once the condition has already stabilized.

A newer treatment that lowers harmful antibodies

The most significant new treatment for CIDP in recent years takes a different approach from the immunoglobulin therapies. Rather than adding donated antibodies, it lowers the level of the body’s own antibodies, including the harmful ones attacking the nerves.

It does this by blocking a natural recycling system that normally keeps antibodies circulating in the blood for a long time. With that recycling switched off, more of the harmful antibodies are broken down and cleared, which reduces the attack on the nerves.

It is given as a small injection under the skin, usually once a week, and in some cases can be self-administered. In studies, it lowered the chance of the condition worsening compared with an inactive placebo, and many people saw improvements in movement and strength.

Because it lowers antibody levels, the most common side effects relate to a higher chance of minor infections, along with headache and occasional injection-site reactions. It is often considered for people who have not responded well to, or could not tolerate, the immunoglobulin treatments.

Longer-term corticosteroids

Corticosteroids can also play a maintenance role, though their side-effect burden usually leads doctors to reduce them over time or to pair them with another treatment so that a lower dose can be used.

For some people, a small ongoing dose helps keep the condition stable. That benefit is always weighed carefully against the long-term risks of staying on steroids.

When first-line treatment is not enough

Not everyone responds to the first treatment they try. This is not a dead end, and several routes forward exist.

The first step is often an unexpected one: revisiting the diagnosis. A number of other conditions can resemble CIDP, and a treatment that is not working can be a sign that something else is going on. Confirming the diagnosis prevents months of treatment aimed at the wrong target.

If the diagnosis holds, the next step is usually to switch between the first-line treatments, since many people who do not respond to one do well on another. Plasma exchange is sometimes introduced here, when immunoglobulin or corticosteroids have not done enough on their own.

When the established treatments have been exhausted, doctors may turn to medicines that calm the immune system more broadly. These are often borrowed from the treatment of other immune conditions and include azathioprine, mycophenolate, methotrexate, and, in more severe cases, cyclophosphamide. The evidence for them in CIDP is more limited, so the choice is highly individual and weighed carefully against the side effects involved.

Another option for difficult cases is a treatment that lowers the specific immune cells responsible for making antibodies, known as B cells. Reducing these cells can quiet the antibody-driven attack on the nerves. It appears to be most helpful for a particular form of CIDP linked to certain antibodies, where the usual immunoglobulin treatment often works less well.

In rare, severe cases that have resisted every other approach, a more intensive treatment that resets the immune system using a person’s own stem cells may be considered. It is reserved for a small number of people because of the risks involved.

Research into CIDP is ongoing, and new approaches continue to be studied over time. Anyone interested in current research can discuss the available options with their neurologist.

Supportive care alongside treatment

The treatments above target the immune attack itself, but managing CIDP well usually involves more than that. Supportive care works alongside the main treatment to rebuild strength, protect function, and ease the symptoms that linger.

• Physical therapy rebuilds strength, balance, and stamina, and lowers the risk of falls. A steady, structured program over several weeks tends to be far more useful than occasional effort.
• Occupational therapy focuses on everyday activities. It identifies practical adjustments and tools for tasks that become harder when the hands and fingers are affected, such as buttoning a shirt, gripping a pen, or working in the kitchen.
• Pain management matters because nerve pain is common in CIDP, and it does not respond well to ordinary painkillers. Medicines developed for nerve pain, such as gabapentin, pregabalin, or duloxetine, are often more effective.
• Mental health support is an important and frequently overlooked part of care. Living with a long-term condition takes a real toll, and anxiety and low mood are more common in people with CIDP than in the general population. Counseling, peer support, and, where appropriate, treatment all have a place.

How treatment decisions are made

With several effective options available, choosing a treatment for CIDP is rarely a matter of one being simply better than the rest. A neurologist weighs several factors together with the person being treated.

• How severe and fast-moving the condition is. Symptoms that are worsening quickly may call for a treatment that acts fast, while milder, slower disease leaves more room to weigh convenience and side effects.
• The form of CIDP. Different variants behave differently, and some are known to respond better to particular treatments.
• Other health conditions. Existing issues such as diabetes, high blood pressure, or a tendency toward infections can make one treatment a safer choice than another.
• Daily life and personal preference. How a treatment fits into daily life carries real weight. Some people prefer the independence of treating themselves at home, while others feel more secure with infusions supervised by a care team. Frequency, travel, and time all factor in.
• Response and tolerability. No treatment plan is fixed. Doctors monitor how well a treatment works and how well it is tolerated, and adjust over time. Finding the lowest effective dose that keeps the condition stable is a common long-term goal.

What to expect from treatment

Recovery in CIDP is usually a gradual process rather than a sudden change.

For many people, the first sign that treatment is working is that the decline stops. Stabilizing the condition is itself an important result, and measurable gains in strength and sensation tend to follow more slowly, over weeks and months.

It is also realistic to expect that some symptoms may remain even when treatment is working. Lingering fatigue, mild weakness, or altered sensation are common, particularly if there was nerve damage before treatment began. This does not mean the treatment has failed. It reflects the difference between calming the immune attack, which treatment does well, and fully repairing nerves that were already damaged, which takes longer and is not always complete.

Remission is a genuine possibility. A meaningful share of people are eventually able to reduce or even stop treatment while remaining stable, and this is more likely for those diagnosed and treated early, and at a younger age. Because the condition can return, any reduction in treatment is done carefully and with monitoring, so that a relapse can be caught and treated quickly.

Questions to discuss with a neurologist

Treatment works best as a partnership. The following questions can help guide a conversation with a neurologist experienced in CIDP:

• What is the goal of this treatment plan, and what would success look like?
• How and when will we know whether it is working?
• Which side effects should be watched for, and which ones need urgent attention?
• What are the options if this treatment does not do enough?
• Is there an approach that would allow more independence or a lighter schedule?
• Over the longer term, could treatment be reduced, and how would that be done safely?

Frequently asked questions

Can CIDP actually be cured, or am I on these drugs for life?

There is no outright cure for CIDP, but lifelong treatment is not inevitable for everyone. The condition can often be brought under good control, and a meaningful share of people eventually reach a lasting remission that allows them to reduce or stop treatment while remaining stable. Long-term studies put that figure at roughly a quarter to a third of people, and it is more likely for those diagnosed early and at a younger age. Others do need ongoing treatment to stay steady. In all cases, stepping treatment down is done gradually and with monitoring, because the condition can return.

Is CIDP a lifelong condition?

For most people, CIDP is a long-term condition that needs ongoing management, but its course varies considerably from one person to the next. The most common pattern is a slow, steady one that requires continued treatment to keep it in check. A smaller group has a relapsing pattern, with flare-ups followed by periods of recovery, and a few have a single episode that resolves and does not return. Even when CIDP is controlled rather than gone, many people live full and active lives, particularly when the condition is caught early and treated consistently.

How long does it take for IVIg to start working?

Many people notice a change within the first one to two weeks, often as their decline slowing or stopping before strength begins to return. On average, measurable improvement appears around the four-week mark, though some people respond faster and others more slowly. The fullest benefit can take several months of regular infusions to build. For this reason, one or two infusions is usually too early to judge whether IVIG is working.

Why am I still so tired and weak if my doctor says the treatment is working?

This is a common experience, and it does not mean the treatment is failing. Treatment is effective at calming the immune attack, but the nerves themselves heal slowly, and some damage may not fully reverse. Fatigue in particular is one of the most persistent features of CIDP and can remain even while strength and sensation are improving in other ways. It can also have its own separate causes that controlling the inflammation does not address. Pacing activity, building strength gradually through physical therapy, and raising ongoing fatigue with a care team all help. It is worth discussing rather than simply enduring.

What are the new treatments if standard therapies fail?

When the standard treatments do not do enough, several further options remain. The first step is usually to confirm the diagnosis, since a poor response can be a sign of a different condition. After that, doctors may switch between the standard treatments, because some people respond to one and not another. Beyond those, the options include medicines that calm the immune system more broadly, a treatment that lowers the immune cells responsible for making antibodies, and a newer treatment that reduces the body’s own harmful antibodies by blocking the system that keeps them in circulation. In rare, severe cases that resist every other approach, a more intensive treatment that resets the immune system may be considered. The right choice is highly individual, which is why it is worked out with a neurologist experienced in CIDP.

Working with a CIDP care team

CIDP is a condition with real, effective treatments and, for many people, a genuinely hopeful outlook.

The range of options available in 2026 means that even when one approach does not work, others remain, and the plan can be adjusted as circumstances change. Standard treatments backed by decades of evidence now sit alongside newer arrivals that offer more flexibility and a different mechanism, giving neurologists and patients more to work with than ever before.

What matters most is working closely with a neurologist experienced in CIDP, starting treatment early to protect the nerves, and staying in regular contact so the plan can evolve. With the right care, many people regain strength, bring their symptoms under control, and return to the activities that matter to them.